Stelis Biopharma

Showing: 1 - 1 of 1 Articles

Syngene to acquire multi-modal facility from Stelis Biopharma Ltd, adding 20,000 liters of installed biologics drug substance manufacturing capacity, with scope for further expansion, and a high speed, commercial scale, fill-finish unit

Syngene today announced the acquisition of Unit 3 biologics manufacturing facility in Bangalore, India, from …